1. Braun SR. Promoting “low T”: a medical writer’s perspective. JAMA Int Med. 2013;173:1458–60.
2. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.
3. FDA. FDA adding general warning to testosterone products about potential for venous blood clots. http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm . Accessed 19 Jun 2014.
4. Health Canada. Information update—possible cardiovascular problems associated with testosterone products. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/40587a-eng.php . Accessed 15 Jul 2014.
5. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm . Accessed 3 Mar 2015.